Reports Q3 group sales GBP8.1B. Pharmaceuticals GBP 4.2 billion, +1% AER, +3% CER; Vaccines GBP 1.9 billion, +14% AER, +17% CER; Consumer Healthcare GBP 1.9 billion, -1% AER, +3% CER. Adjusted Group operating margin of 31.2%, -0.3 percentage points AER; +0.2 percentage points CER. Pharmaceuticals 32.2%; Vaccines 43.0%; Consumer Healthcare 22.0%. Emma Walmsley, CEO, said: “GSK has made further good progress this quarter with CER sales growth in all three businesses, improvements in the Group operating margin at CER and Adjusted earnings per share growth of 14%. Strong commercial execution for key products and new launches, notably Shingrix, together with an effective focus on cost control is driving this improved performance and we now expect 2018 Adjusted EPS growth of 8-10% at CER. Looking further ahead, we remain confident in our ability to deliver the Group outlooks for sales and EPS growth we previously set for the period 2016-2020.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.